FDA approves Ruzurgi pill to treat Lambert-Eaton muscle weakness syndrome at age 6-17
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
LEMS is a rare autoimmune disease that affects the connection between nerves and muscles, leading to muscle weakness and other symptomsLemS patients with their own immune systems attack neuromuscular junctions (NMJ), blocking the transmission of nerve signals into muscle cellstoday,the fda
(http://announced the approval of theof, a, of Jacobushttp://
Pharmaceuticals, to be available for the treatment of Lambert-Eaton muscle weakness syndrome (LEMS) patients aged 6-17Ruzurgi's approval is based on clinicaltrial(http://in adult LEMS patients, pharmacokinetic data in adult patients, as well as the use of pharmacokinetic models and simulated pediatric patient doses, and safety data obtained from pediatric patients aged 6-17 yearsRuzurgi's efficacy is based on randomized double-blind, placebo-controlled clinical studies in 32 adult patientsIn the study, patients first used Ruzurgi for three months, then some patients continued to use Ruzurgi, while others switched to placebo treatment results showed that patients who continued to receive Ruzurgi were less likely to have less motor capacity than in the placebo group
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
